Sandbox GGC11: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
Student (talk | contribs)
students
33,923 edits
No edit summary
Student (talk | contribs)
students
33,923 edits
No edit summary
 
(16 intermediate revisions by the same user not shown)
Line 1: Line 1:
==5CEQ DLK in complex with inhibitor 50F (2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile)==
==5CEQ DLK in complex with inhibitor 50F (2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile)==
<StructureSection load='5CEQ' size='340' side='right' caption='5ceq=''>
<StructureSection load='5ceq' size='340' side='right'caption='[[5ceq]], [[Resolution|resolution]] 1.91&Aring;' scene=''>
5CEQ is a This is a default text for your page. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
5CEQ is a MAP3K12 protein from homo sapiens. It plays a role in the MAPK Cascade pathway mostly by interacting with the JNKs, SAPKs, and ERKs which are part of part of the MAP kinases. Since some of the MAP kinases are involved with the central nervous system signaling, it has been shown that DLK also plays a role in protection of neurons when inhibited by 50F.  
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.


== Function ==
== Function ==
 
Regulates JNK/SAPK cascade, transferase phosphorylation
== Disease ==
== Disease ==
 
Neuron degenerative diseases such as Parkinson’s, and Alzheimer.
== Relevance ==
== Relevance ==
This protein will help us understand more about the physiology of degenerative diseases, which will lead to making more medicine that could possibly slow the deterioration process, or even cure the diseases.
== Structural highlights ==
<scene name='78/781195/00ligand/1'>50F</scene>


== Structural highlights ==
<scene name='78/781195/01dfg_active_site/1'>active site</scene>


This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
<scene name='78/781195/03asp161/1'>ASP161</scene>


</StructureSection>
</StructureSection>
Gene: MAP3K12
Related proteins: 5CEO, 5CEN, Q12852
Ligand: 50F
== References ==
== References ==
<references/>
1. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y, Ma C, Scearce-Levie K, Ghosh AS, Shin YG, Solanoy H, Wang J, Wang B, Yin J, Siu M, Lewcock JW. Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12). J Med Chem. 2015 Oct 2. PMID:26431428 doi:http://dx.doi.org/10.1021/acs.jmedchem.5b01072
 
2.  Cargnello, M., & Roux, P. P. (2011). Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiology and molecular biology reviews : MMBR, 75(1), 50–83. https://doi.org/10.1128/MMBR.00031-10
 
3. Siu M, Sengupta Ghosh A, Lewcock JW. Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration. J Med Chem. 2018 Sep 27;61(18):8078-8087. doi: 10.1021/acs.jmedchem.8b00370. Epub 2018 Jun 4. PMID: 29863360.
 
4. Patel S, Cohen F, Dean BJ, De La Torre K, Deshmukh G, Estrada AA, Ghosh AS, Gibbons P, Gustafson A, Huestis MP, Le Pichon CE, Lin H, Liu W, Liu X, Liu Y, Ly CQ, Lyssikatos JP, Ma C, Scearce-Levie K, Shin YG, Solanoy H, Stark KL, Wang J, Wang B, Zhao X, Lewcock JW, Siu M. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem. 2015 Jan 8;58(1):401-18. doi: 10.1021/jm5013984. Epub 2014 Oct 23. PMID: 25341110./>
Retrieved from "https://proteopedia.org/Sandbox_GGC11"